Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Tag Archives: ip
Microsoft V. i4i – Prosecution And The “Variable Proof Regime”
The Government recently weighed in on this important appeal with its amicus brief, signed by Neal Katyal, Acting Solicitor General. (A copy can be found at the end of this post.) The question posed is simply: “Whether, when the defendant … Continue reading
Innovation Toys And Analogous Art – Defender Against Hindsight?
There is nothing particularly surprising in the recent Fed. Cir. decision of Innovation Toys v. MGA Entertainment, App. No. 2010-1290 (Fed. Cir. March 21, 2011) (a copy is available at the end of this post), which reversed a District Court finding … Continue reading
One step ahead and one step backward for the EU patent
The following is a contribution from Camilla Rendal Nielsen of Zacco Denmark A/S 1. The EU Competiveness Council have authorised “enhanced cooperation” in the area of unitary patent protection, and. 2. The EU court now states that the proposed Patents Court … Continue reading
Posted in Non-U.S. Practice
Tagged camilla rendal nielsen, EPO, EU Treaty, European patent, intellectual property, ip, IP law tools, Patent Law, patents, Warren Woessner, zacco
Leave a comment
Canadian Ruling Supports “Antibody Exception”
In my recent post on the Centocor v. Abbott decision, I noted that the Fed. Cir. had at least preserved the “antibody exception,” which I define as permitting broad claims to structurally uncharacterized antibodies (monoclonal and polyclonal) if the structure … Continue reading